Crohn’s disease management has little to no standardization,1,2 leading to clinical and economic inefficiencies. There is an emerging need for more efficient and complete intestinal visualization to make quantitative assessments of mucosal healing.
The PillCam™ Crohn’s system offers a solution by obtaining direct visualization of the entire small bowel and colonic mucosa with a noninvasive procedure.
This webpage and all associated resources are specific only to the EU. Indications for other markets, such as the U.S., may vary.
References: 1. Dionisio PM, Gurudu SR, Leighton JA, Leontiadis GI, Fleischer DE, Hara AK, et al. Capsule Endoscopy Has a Significantly Higher Diagnostic Yield in Patients With Suspected and Established Small-Bowel Crohn’s Disease: A Meta-Analysis. Am J Gastroenterol. 2010;105:1240-8. 2. Rogler G, Biedermann, L. Clinical Utility of Biomarkers in IBD. Current Gastroenterology Reports. 2015;17:26.Risk Information: The risks of the PillCam™ Crohn’s capsule include capsule retention, aspiration, and skin irritation. The risks associated with colon preparation are allergies or other known contraindications to any preparation agents or medications used for the PillCam™ Crohn’s system regimen, according to laxative medication labeling and per physician discretion. Medical, endoscopic, or surgical intervention may be necessary to address any of these complications, should they occur. After ingesting the PillCam™ Crohn’s capsule, and until the capsule is excreted, patients should not be near any source of powerful electromagnetic fields, such as one created near an MRI device. Please refer to the product user manual or pillcamcrohnscapsule.eu for detailed information.
16-eu-pillcam-sbc-microsite-1289890
